David E. Redlick

Much of Mr. Redlick’s practice involves companies in the life sciences industry. Chambers and Partners ranks Mr. Redlick in Band 1 in the life sciences: commercial category for both the United States and globally.

Recent transactions in which he has served as counsel include representation of: Epizyme, PTC Therapeutics, Merrimack Pharmaceuticals and Verastem in their initial public offerings, Ophthotech in its pending initial public offering and OvaScience in its Form 10 “public offering”; The Medicines Company in a $250 million convertible note offering and $200 million follow on common stock offering; Ophthotech in its $175 million synthetic royalty and Series C preferred stock financing led by Novo A/S; and Ista Pharmaceuticals in its acquisition by Bausch+Lomb and The Medicines Company in its acquisitions of Incline Therapeutics and ProFibrix.

Mr. Redlick is a member of the Overseers Committee of Brigham and Women’s Hospital. Mr. Redlick has lectured at Harvard Law School, the Kellogg School of Management at Northwestern University and the Sloan School of Management of The Massachusetts Institute of Technology on public offerings. He is also a frequent speaker about partnering and M&A in the biopharma industry.

Mr. Redlick received a JD from Harvard Law School and a BA from the University of Wisconsin.